- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02723435
Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant
An Open-Label Extension Study of Post-Transplant Maintenance Midostaurin (PKC412) in Elderly Patients (Age ≥ 60 Years) With FLT3-ITD/TKD Mutated AML Who Previously Received Midostaurin and Decitabine as Part of Study HEMAML0022 / CPKC412AUS27T
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the efficacy and safety of maintenance midostaurin (a fms related tyrosine kinase 3 [FLT3] inhibitor) for elderly patients with FLT3-internal tandem duplication (ITD)/tyrosine kinase domain (TKD) mutated acute myeloid leukemia (AML) who were previously enrolled on study HEMAML0022/CPKC412AUS27T and have then undergone allogeneic transplant.
SECONDARY OBJECTIVES:
I. To determine whether maintenance midostaurin after allogeneic transplant decreases the relapse rate in patients with FLT3-ITD/TKD mutated AML.
OUTLINE:
Beginning 30 days post-hematopoietic cell transplantation (HCT), patients receive midostaurin orally (PO) twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then up to 1 year.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA
- Elderly patients with FLT3-mutated acute myeloid leukemia (AML)
- Prior enrollment in Stanford study IRB-25737
- In continued complete remission
- ≥ 30 days but ≤ 90 days post allogeneic hematopoietic cell transplant (HCT); treatment on this study protocol must begin before day 90 post-HCT
- Absolute neutrophil count (ANC) ≥ 1000 cells/uL
- Hemoglobin ≥ 8.0 g/dL and not requiring regular transfusions
- Platelets ≥ 50,000 cells/uL and not requiring regular transfusions
- Aspartate aminotransferase (AST) ≤ 2.5 times upper limit of normal (ULN)
- Alanine aminotransferase (ALT) ≤ 2.5 X ULN
- Serum bilirubin ≤ 2.5 times ULN
- Ability to give written informed consent, including via legally authorized representative
- Corrected QT (QTc) ≤ 450 msec
- Ejection fraction (EF) ≥ 45% by 2-dimensional transthoracic echocardiography (TTE) or multiple-gated acquisition (MUGA)
- Sexually active males, including vasectomized males, must agree via informed consent to use a condom during vaginal, anal, or oral intercourse, while taking midostaurin and for 5 months after stopping midostaurin
Females must have or be:
- Negative pregnancy test, within 21 days of the first dose of midostaurin OR
Not of childbearing potential as follows:
- Has undergone a hysterectomy or bilateral oophorectomy;
- Has not had menses at any time in the preceding 24 consecutive months
EXCLUSION CRITERIA
- Uncontrolled acute graft-vs-host disease (GVHD) grade 3 to 4
- Uncontrolled active infection
- Evidence of active AML (eg, circulating peripheral blasts on complete blood count)
- Known confirmed diagnosis of human immunodeficiency virus (HIV) infection
- Known confirmed diagnosis of active viral hepatitis
- QTc > 450 msec
- Congenital long QT syndrome
- History of presence of sustained ventricular tachycardia, history of ventricular fibrillation or torsades de pointes
- Bradycardia defined as heart rate (HR) < 50 beats per minute (bpm)
- Bifascicular block (right bundle branch block plus left anterior hemiblock)
- Congestive heart failure (CHF) New York Heart Association (NYHA) class 3 or 4
- Cardiac ejection fraction (EF) < 45% within 28 days prior to starting cycle 1
- Other known malignancy (except carcinoma in situ)
Other concurrent severe and/or uncontrolled medical condition which could compromise participation in the study, eg:
- Uncontrolled diabetes
- Chronic active pancreatitis
- Myocardial infarction within 6 months
- Poorly-controlled hypertension
- Chronic kidney disease
- Received any investigational agent within 30 days prior to day 1
- Antineoplastic chemotherapy or radiotherapy within 28 days prior to cycle 1
- No plans for concurrent chemotherapy while on study (exception: antineoplastic drugs used as part of GVHD prophylaxis or treatment)
- Any surgical procedure, excluding central venous catheter placement, bone marrow biopsy or other minor procedures (eg, skin biopsy) within 14 days of day 1
- Unwillingness or inability to comply with the protocol
- Known malignant disease of the central nervous system
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to midostaurin
- Concomitant use of strong inhibitors of cytochrome P450 family 3 subfamily A member 4 (CYP3A4)
- Pregnant or lactating
- Women of child-bearing potential
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Midostaurin
Beginning 30 days post-HCT, participants receive oral midostaurin twice-a-day in 28-day treatment cycles, continuing up to 12 cycles in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event-free survival
Time Frame: Up to 1 year
|
Up to 1 year
|
|
Incidence of adverse events using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Time Frame: Up to 30 days
|
Up to 30 days
|
|
Overall survival
Time Frame: Up to 1 year
|
Calculated and reported with Kaplan Meier curves.
The statistical analyses will focus on estimation rather than hypothesis testing.
Two-sided 95% confidence intervals will be presented, using the Clopper-Pearson method for proportions and using Greenwood's formula for time to event outcomes.
|
Up to 1 year
|
Relapse free survival
Time Frame: Up to 1 year
|
Calculated and reported with Kaplan Meier curves.
The statistical analyses will focus on estimation rather than hypothesis testing.
Two-sided 95% confidence intervals will be presented, using the Clopper-Pearson method for proportions and using Greenwood's formula for time to event outcomes.
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse rate after allogeneic transplant
Time Frame: Up to 1 year
|
Described using proportions.
|
Up to 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Iberri, MD, Stanford University
Study record dates
Study Major Dates
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-31582
- NCI-2016-00424 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- HEMAML0022-EXT (Other Identifier: OnCore)
- NCT02723435 (Other Identifier: Stanford University)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adult Acute Myeloid Leukemia in Remission
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnAdult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in RemissionUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedAdult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in RemissionUnited States
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownAdult Acute Myeloid Leukemia in RemissionItaly
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission | Recurrent... and other conditionsUnited States
-
University of Colorado, DenverThe Leukemia and Lymphoma SocietyCompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in RemissionUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingPreviously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Adult Acute Myeloid Leukemia... and other conditionsUnited States
-
Center for International Blood and Marrow Transplant...National Marrow Donor ProgramRecruitingAcute Myeloid Leukemia in RemissionUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Adult Acute Myeloid Leukemia... and other conditionsUnited States
Clinical Trials on Midostaurin
-
University Medical Center GroningenUnknown
-
Novartis PharmaceuticalsAvailableAcute Myeloid Leukemia | Mast Cell Leukemia | Aggressive Systemic Mastocytosis | Systemic Mastocytosis With an Associated Hematologic Neoplasm | FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia
-
Novartis PharmaceuticalsCompletedAML and High Risk MDSGermany, Italy, France, Netherlands, United States, Australia, Japan
-
Novartis PharmaceuticalsCompletedLeukemiaUnited States, Belgium, Netherlands, Canada, Austria, Germany, Australia, United Kingdom, Turkey, France, Poland, Norway
-
Novartis PharmaceuticalsTerminatedAcute Myeloid Leukemia | Acute Lymphoblastic LeukemiaSweden, Italy, France, United States, Netherlands
-
Technische Universität DresdenNovartis PharmaceuticalsCompletedAcute Myeloid LeukemiaGermany
-
University of KansasNovartisCompletedAcute Myeloid LeukemiaUnited States
-
Technische Universität DresdenPfizer; Novartis PharmaceuticalsRecruiting
-
Novartis PharmaceuticalsRecruitingFollicular Lymphoma | Acute Lymphoblastic Leukemia | Diffuse Large B-cell LymphomaBrazil
-
Richard Stone, MDMassachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's HospitalActive, not recruitingRAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDSAcute Myeloid Leukemia | Myelodysplastic SyndromeUnited States